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n October 2015, the Centers for Disease Control 
and Prevention’s (CDC) Advisory Committee on 
Immunization Practices recommended that 
adolescents and young adults ages 16 to 23 
years old might be vaccinated with serogroup B 
meningococcal vaccine based on individual clinical 
decision making (Category B recommendation).  
A recent article published in Pediatrics found that 
during routine visits, 51 percent of pediatricians 
and 31 percent of family practitioners reported 
always or often discussing the MenB vaccine with 
their patients. Among those who discussed the 
topic often or always, 91 percent recommended  
the vaccination; among those who never or rarely 
discussed the vaccine, 11 percent recommended it.1 
IMeningococcal B VaccineAre you discussing this with your 16 to 23 
year old patients?
Ellen Link, MD
iowaepsdt.org [2]                Winter 2019  EPSDT Care for Kids Newsletter   
In September 2016 the American Academy of Pediatrics 
(AAP) issued a policy statement regarding Meningitis B 
Vaccine Recommendations.3 They noted that there were 
two serogroup B meningococcal vaccines available, 
MenB-FHbp (Trumenba) and MenB-4C (Bexsero). Both 
are licensed for use in persons 10 to 25 years of age. 
Trumenba is administered as a 3-dose series for those  
at increased risk of meningococcal B disease and as a 
2-dose series for those not at increased risk. Bexsero is 
administered as a 2-dose series for all groups. The first 
dose of Bexsero should be administered at day 0, and 
the second dose should be administered ≥1 month 
later; the 3-dose series of Trumenba should be 
administered on a 0-, 1- to 2-, and 6-month schedule. 
The table below from the policy statement highlights 
the high-risk recommendations.
The study was a survey done between October and 
December 2016 among pediatricians and family 
physicians who were part of sentinel networks within 
each specialty. An additional finding was that those 
somewhat or not at all aware of the MenB vaccine and 
those practicing in a health maintenance organization 
were less likely to recommend the vaccine, whereas  
those aware of disease outbreaks in their state were  
more likely to discuss MenB vaccine with their patients. 
The authors concluded that primary care physicians have 
significant gaps in knowledge about MenB disease  
and the MenB vaccine, and this appears to be a major 
driver of the decision not to discuss the vaccine.
Meningococcal disease presents clinically as meningitis 
(fever, headache, and stiff neck), and sepsis and rash in 
meningococcemia. Neisseria meningitidis serogroups  
B, C, and Y cause the majority of disease in the United  
States and serogroup W causes a small portion of disease. 
Serogroup A causes disease in developing countries. 
Rates of meningococcal disease have been declining  
in the United States since the 1990s. Rates of disease  
are highest in children younger than one year with a 
second peak in adolescence.2
Significant sequelae are associated with Neisseria 
meningitidis infections. Ten to 15 people out of 100 
infected with meningococcal disease will die. About  
11 to 19 survivors out of every 100 will have long-term 
disabilities, including loss of limb, deafness, neurologic 
problems, or brain damage. The disease is spread by 
exchanging respiratory and throat secretions during  
close or lengthy contact, especially if living in the  
same household.2
In February 2015, the Advisory Committee on 
Immunization Practices (ACIP) of the CDC recommended 
the routine use of MenB vaccines in persons 10 years  
and older at increased risk of the disease (Category A 
recommendation). In June 2015 the ACIP stated that 
healthy adolescents and young adults 16 to 23 years of 
age (preferred ages, 16 to 18) who are not at increased 
risk of serogroup B meningococcal disease may be 
considered for vaccination with a MenB vaccine. This 
provides short-term protection against most strains  
of serogroup B meningococcal disease (the Category B 
recommendation), but routine immunization is not 
recommended.  
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The policy statement notes 
that meningococcal disease 
caused by any serogroup in 
the U.S. is rare, but can be life 
threatening. Despite recent 
outbreaks on college 
campuses, the incidence of 
serogroup B meningococcal 
disease in college students is 
similar to or lower than the 
incidence in all 18 to 23 year 
olds and noncollege students. 
Both vaccines appear to 
provide short-term 
immunogenicity in healthy 
individuals. Licensure was 
based on the ability of the 
vaccines to elicit detection of 
bactericidal antibodies that 
presumably indicate protection. Information regarding 
antibody persistence is limited. There are theoretical 
concerns of autoimmune disease after receipt of a 
vaccine containing FHbp antigen. 
(continues on page 4)
TABLE 1 
Increased Risk Groups Recommended for the Different Meningococcal Vaccines
MenACWY MenB
Complement deficiencya Complement deficiencya






↵a Inherited or chronic deficiencies of C3, C5–C9, properdin, factor D, or factor H or those receiving eculizumab
↵b Includes sickle cell disease
↵c The CDC defines outbreaks and those at risk
↵d Only microbiologists who routinely work with N meningitidis
↵e To areas with hyperendemic or epidemic meningococcal disease
↵f Unvaccinated or inadequately vaccinated first-year college students who live in residence halls
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TABLE 2
Local and Systemic Adverse Events Reported in Clinical Trials for MenB-4C and MenB-FHbp
Adverse Event MenB-4C (Bexsero), % MenB-FHbp (Trumenba), %
Severe pain at injection site 20–29 5–8
Fever ≥38 C 1–5 2–8
Headache (severe) 4–6 1
Fatigue (severe) 4–6 1–4
Muscle pain (severe) 12–13 1–3
Joint pain (severe) 2 1
Use of antipyretic medication NA 17– 28
Clinical trials have shown both vaccines to be safe with few serious adverse events, which have all resolved.  
The table below summarizes these adverse events. Post-marketing studies are being conducted.  
Resources
1. Kempe A, Allison MA, MacNeil JR, et al. Adoption of serogroup B meningococcal vaccine recommendations.  
Pediatrics. 2018;142(3):e20180344.
2. Centers for Disease Control and Prevention (CDC). Meningococcal Disease: Technical and Clinical Information.  
Available at https://www.cdc.gov/meningococcal/clinical-info.html  Accessed September 26, 2018.  
3. AAP Committee on Infectious Diseases. Recommendations for Serogroup B Meningococcal Vaccine for Persons 10 Years and Older. 
Pediatrics. 2016;138(3).
The AAP policy statement on serogroup B Meningococcal 
Vaccine made the following summary recommendations:
Persons 10 years and older at increased risk of 
meningococcal disease should receive a MenB vaccine 
routinely (Category A recommendation for all three of  
the following groups):
(a) persons with persistent complement component 
deficiencies, including inherited or chronic deficiencies 
in C3, C5–C9, properdin, factor D, or factor H or those 
receiving eculizumab;
(b) persons with anatomic or functional asplenia, 
including sickle cell disease; and
(c) healthy persons identified to be at increased risk 
because of a serogroup B meningococcal disease 
outbreak (defined by local health departments on  
the basis of CDC criteria); these persons should  
receive a MenB vaccine series if their treating health 
care providers, in consultation with their local health  
or state departments, determine they are appropriate 
candidates on the basis of CDC criteria.
A MenB vaccine series is not routinely recommended, but 
it may be administered to adolescents and young adults 
16 to 23 years of age to provide short-term protection 
against diverse strains of serogroup B meningococcal 
disease (Category B recommendation). If a MenB vaccine 
is administered, the preferred age for MenB vaccination is 
between 16 to 18 years old. This age preference is based 
on limited data on antibody persistence and the peak 
ages of invasive serogroup B meningococcal disease.
Primary care providers should discuss the availability of 
the MenB vaccine with their adolescent patients, ideally 
at 16 to 18 years of age. This should include the low 
incidence but severity of the disease, as well as the 
unknown efficacy of the vaccine. Discussion also should 
include that both vaccines have been shown safe with 
few serious side effects in clinical trials and that ongoing 
data collection is occurring. Benefits, risks, and costs 
should be discussed with patients and their families  
to determine if the vaccine is appropriate for them. 
Additional details regarding the vaccines can be found  
in the package inserts and in the following resources. 
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Many Vaccine Information Statements are 
available in Spanish and other languages. 
See www.immunize.org/vis
Hojas de información sobre vacunas están 
disponibles en español y en muchos otros 
idiomas. Visite www.immunize.org/vis
Serogroup B Meningococcal Vaccine (MenB):
What You Need to Know
1 Why get vaccinated?
Meningococcal disease is a serious illness caused by a 
type of bacteria called Neisseria meningitidis. It can lead 
to meningitis (infection of the lining of the brain and 
spinal cord) and infections of the blood. Meningococcal 
disease often occurs without warning — even among 
people who are otherwise healthy.
Meningococcal disease can spread from person to 
person through close contact (coughing or kissing) or 
lengthy contact, especially among people living in the 
same household.
There are at least 12 types of N. meningitidis, called 
“serogroups.” Serogroups A, B, C, W, and Y cause most 
meningococcal disease.
Anyone can get meningococcal disease but certain 
people are at increased risk, including:
• Infants younger than one year old
• Adolescents and young adults 16 through 23 years old
• People with certain medical conditions that affect the
immune system
• Microbiologists who routinely work with isolates of
N. meningitidis
• People at risk because of an outbreak in their
community
Even when it is treated, meningococcal disease kills 
10 to 15 infected people out of 100. And of those who 
survive, about 10 to 20 out of every 100 will suffer 
disabilities such as hearing loss, brain damage, kidney 
damage, amputations, nervous system problems, or 
severe scars from skin grafts.
Serogroup B meningococcal (MenB) vaccines can help 
prevent meningococcal disease caused by serogroup B. 
Other meningococcal vaccines are recommended to help 
protect against serogroups A, C, W, and Y.
 2  Serogroup B Meningococcal Vaccines
Two serogroup B meningococcal vaccines — Bexsero®
and Trumenba® — have been licensed by the Food and 
Drug Administration (FDA).
These vaccines are recommended routinely for people 10 
years or older who are at increased risk for serogroup B 
meningococcal infections, including:
• People at risk because of a serogroup B meningococcal
disease outbreak
• Anyone whose spleen is damaged or has been removed
• Anyone with a rare immune system condition called
“persistent	complement	component	deficiency”
• Anyone taking a drug called eculizumab (also called
Soliris®)
• Microbiologists who routinely work with isolates of
N. meningitidis
These vaccines may also be given to anyone 16 through 
23 years old to provide short term protection against 
most strains of serogroup B meningococcal disease; 16 
through 18 years are the preferred ages for vaccination.
For best protection, more than 1 dose of a serogroup B 
meningococcal vaccine is needed. The same vaccine 
must be used for all doses. Ask your health care provider 
about the number and timing of doses.
 3  Some people should not get these vaccines
Tell the person who is giving you the vaccine:
• If you have any severe, life-threatening allergies. 
If you have ever had a life-threatening allergic reaction	
after a previous dose of serogroup B meningococcal	
vaccine, or if you have a severe allergy to any part of	
this vaccine, you should not get the vaccine. Tell your 
health care provider if you have any severe allergies 
that you know of, including a severe allergy to latex. 
He	or she can tell you about the vaccine’s ingredients.
• If you are pregnant or breastfeeding.
There is not very much information about the
potential risks of this vaccine for a pregnant woman
or breastfeeding mother. It should be used during
pregnancy only if clearly needed.
If you have a mild illness, such as a cold, you can 
probably get the vaccine today. If you are moderately or 
severely ill, you should probably wait until you recover. 
Your doctor can advise you.
U.S. Department of 
Health and Human Services 
Centers for Disease 
Control and Prevention 
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 4 Risks of a vaccine reaction
With any medicine, including vaccines, there is a chance 
of reactions. These are usually mild and go away on their 
own within a few days, but serious reactions are also 
possible. 
More than half of the people who get serogroup B 
meningococcal vaccine have mild problems following 
vaccination. These reactions can last up to 3 to 7 days, 
and include:
•	 Soreness, redness, or swelling where the shot 
was given 
•	 Tiredness or fatigue
•	 Headache
•	 Muscle or joint pain
•	 Fever or chills
•	 Nausea or diarrhea
Other problems that could happen after these 
vaccines:
•	 People sometimes faint after a medical procedure, 
including vaccination. Sitting or lying down for about 
15 minutes can help prevent fainting and injuries 
caused by a fall. Tell your provider if you feel dizzy, or 
have vision changes or ringing in the ears.
•	 Some people get shoulder pain that can be more severe 
and longer-lasting than the more routine soreness that 
can follow injections. This happens very rarely.
•	 Any medication can cause a severe allergic reaction. 
Such reactions from a vaccine are very rare, estimated 
at about 1 in a million doses, and would happen within 
a few minutes to a few hours after the vaccination.
As with any medicine, there is a very remote chance of a 
vaccine causing a serious injury or death.
The safety of vaccines is always being monitored. For 
more information, visit: www.cdc.gov/vaccinesafety/
 5  What if there is a serious reaction?
What should I look for?
•	 Look for anything that concerns you, such as signs 
of a severe allergic reaction, very high fever, or 
unusual behavior.
Signs of a severe allergic reaction can include hives, 
swelling	of	the	face	and	throat,	difficulty	breathing,	a	
fast heartbeat, dizziness, and weakness. These would 
usually start a few minutes to a few hours after the 
vaccination.
What should I do?
•	 If you think it is a severe allergic reaction or other 
emergency that can’t wait, call 9-1-1 and get to the 
nearest hospital. Otherwise, call your clinic.
Afterward the reaction should be reported to the 
Vaccine Adverse Event Reporting System (VAERS). 
Your	doctor	should	file	this	report,	or	you	can	
do it yourself through the VAERS web site at 
www.vaers.hhs.gov, or by calling 1-800-822-7967.
VAERS does not give medical advice.
 6  The National Vaccine Injury Compensation Program
The National Vaccine Injury Compensation Program 
(VICP) is a federal program that was created to 
compensate people who may have been injured by 
certain vaccines.
Persons who believe they may have been injured by a 
vaccine	can	learn	about	the	program	and	about	filing	a	
claim by calling 1-800-338-2382 or visiting the VICP 
website at www.hrsa.gov/vaccinecompensation. There 
is	a	time	limit	to	file	a	claim	for	compensation.
 7 How can I learn more?
•	 Ask your health care provider. He or she can give you 
the vaccine package insert or suggest other sources of 
information.
•	 Call your local or state health department.
•	 Contact the Centers for Disease Control and 
Prevention (CDC):
- Call 1-800-232-4636 (1-800-CDC-INFO) or
- Visit CDC’s website at www.cdc.gov/vaccines
  Vaccine Information Statement
  Serogroup B Meningococcal Vaccine
  42 U.S.C. § 300aa-26
08/09/2016
Office Use Only





























































































































































































































































































































































































































































































































































    
   

























   



























































   
   
   
   










































































































































































































Please send correspondence concerning content to:
Ellen Link, MD
University of Iowa Health Care
Iowa River Landing, Office 2627
105 9th Street, Coralville, IA  52241
ellen-link@uiowa.edu
Please send change of address information to:
Meredith Field
University of Iowa Stead Family Children’s Hospital 
Center for Disabilities and Development 
100 Hawkins Drive, Iowa City, IA 52242-1011
meredith-field@uiowa.edu
University of Iowa Stead Family Children’s Hospital
Center for Disabilities and Development
University Center for Excellence on Disabilities
100 Hawkins Drive
Iowa City, IA 52242-1011
If you have questions about billing related to EPSDT Care for Kids services, please call 
Provider Services:  1- 800-338-7909. If you have questions about clinical issues and 
EPSDT Care for Kids services, please call 1- 800-383-3826. Please note: Due to budget 
restraints, the EPSDT Care for Kids Newsletter is sent to offices and organizations, rather  
than to individuals. The newsletter is also available online at www.iowaepsdt.org. 
Readers are welcome to photocopy or download material from the newsletter to share 
with others. If you wish to reproduce material from the newsletter in another publication, 
whether print or electronic, please obtain permission prior to publication by contacting 
the editor. Please include the following acknowledgment with reprinted material: 
Reprinted by permission of the Iowa EPSDT Care for Kids Newsletter.
The EPSDT Care for Kids Newsletter is published 
three times a year, in print and online, as a joint 
effort of the Iowa Department of Human Services, 
the Iowa Department of Public Health, and the 
Center for Disabilities and Development, which 
is nationally designated as Iowa’s University 
Center for Excellence on Disabilities. The goal 
of this newsletter is to inform Iowa health care 
professionals about the EPSDT Care for Kids 
program, to encourage them to make use of this 
important resource, and to provide them with 
information about a wide range of developments 
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PLEASE NOTE: Beginning with this issue, a digital version of the EPSDT Care for Kids newsletter will be sent to those on our 
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